VNDA Latest Headlines

FDA Approves Vanda’s NEREUS—First Novel Motion Sickness Drug in 40 Years Spurs Historic Milestone

Market Chameleon (Wed, 31-Dec 9:53 AM)

FDA Application Submission for Imsidolimab Marks a Milestone for Vanda—Phase 3 Data Suggest Durable Benefits for GPP Patients

Market Chameleon (Mon, 15-Dec 11:44 AM)

Vanda's Imsidolimab Application Targets FDA Priority Review: New Hope for Generalized Pustular Psoriasis

Market Chameleon (Mon, 15-Dec 8:37 AM)

FDA Clears Path for Vanda’s Tradipitant: Clinical Hold Lifted and PDUFA Decision Looms

Market Chameleon (Fri, 5-Dec 11:10 AM)

FDA Clears Path for Vanda's Tradipitant in Motion Sickness: PDUFA Date Approaches, Marking First Major Advancement in 40 Years

Market Chameleon (Fri, 5-Dec 8:39 AM)

Tradipitant Study Shows 50% Drop in GLP-1 Induced Vomiting—VNDA Positioned for $50B+ Market Opportunity

Market Chameleon (Tue, 18-Nov 10:31 AM)